79-81
EDITORIAL
Opportunities, challenges, and caveats of successful molecular imaging of cardiovascular diseases
Bodo Levkau
82-86
EDITORIAL
Cardiovascular diseases as target for imaging
Kristof Graf, Michael Gräfe and Eckart Fleck
87-94
REVIEW
MR-optical imaging of cardiovascular molecular targets
Matthias Nahrendorf, David E. Sosnovik and Ralph Weissleder
95-104
REVIEW
Annexin A5: an imaging biomarker of cardiovascular risk
Edward M. Laufer, Chris P. M. Reutelingsperger, Jagat Narula and Leonard Hofstra
105-113
REVIEW
Imaging of stem cells using MRI
Dara L. Kraitchman and Jeff W. M. Bulte
114-121
REVIEW
Contrast agents for MRI
Emily A. Waters and Samuel A. Wickline
122-130
REVIEW
Magnetic nanoparticles for MR imaging: agents, techniques and cardiovascular applications
David E. Sosnovik, Matthias Nahrendorf and Ralph Weissleder
131-143
REVIEW
18F-labelled cardiac PET tracers: selected probes for the molecular imaging of transporters, receptors and proteases
Klaus Kopka, Otmar Schober and Stefan Wagner
144-151
REVIEW
Near-infrared fluorescent probes for imaging vascular pathophysiology
Jan Klohs, Andreas Wunder and Kai Licha
152-160
REVIEW
Structural and functional imaging by MRI
René M. Botnar and Eike Nagel
161-173
REVIEW
Imaging of the heart with computed tomography
Thomas G. Flohr and Bernd M. Ohnesorge
174-181
REVIEW
Ultrasonic imaging of molecular targets
Georg Schmitz
182-190
REVIEW
Optical imaging of vascular pathophysiology
Andreas Wunder and Jan Klohs
191-199
REVIEW
Combined imaging of molecular function and morphology with PET/CT and SPECT/CT: Image fusion and motion correction
Klaus P. Schäfers and Lars Stegger
200-202
OUTLOOK
The future of molecular imaging in the clinic needs a clear strategy and a multidisciplinary effort
M. Schäfers